drugset / Trial / NCT01116440

A Safety & Efficacy Study of BGS649 in Women With Refractory Endometriosis

NCT01116440 ↗

Phase 2 Terminated 27 enrolled Mereo BioPharma Novartis · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine efficacy, safety, tolerability and pharmacokinetics of multiple doses of BGS649 with concurrent daily administration of combined oral contraception in patients with refractory endometriosis

Timeline

Start
2010-04-15
Primary completion
2011-07
Completion
2012-03-21

Drugs

EvaluationDrugModalityDoseRoute
Subject BGS649 Unknown 0.3 mg Oral